Memphasys

Memphasys Interest Expense

The Interest Expense of Memphasys (MEM.AX) as of Oct 20, 2026 is -580,400.00 AUD. In the previous year, Interest Expense was -132,600.00 AUD — a change of 337.71% (lower).

Interest Expense

-580,400.00AUD

YoY

337.71%

Last updated:

Interest Expense of Memphasys is 2025 -580,400.00 AUD. Interest Expense of Memphasys was 2024 -132,600.00 AUD. It decreases by 337.71% lower compared to the previous year.

The Memphasys Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-192,700.00 AUD
Jan 1, 2019
-47,300.00 AUD
Jan 1, 2020
-38,800.00 AUD
Jan 1, 2021
-84,700.00 AUD
Jan 1, 2022
-431,100.00 AUD
Jan 1, 2023
-389,100.00 AUD
Jan 1, 2024
-132,600.00 AUD
Jan 1, 2025
-580,400.00 AUD
The Memphasys Interest Expense history
YEARInterest ExpenseYoY
-580,400.00AUD+337.71%
-132,600.00AUD-65.92%
-389,100.00AUD-9.74%
-431,100.00AUD+408.97%
-84,700.00AUD+118.30%
-38,800.00AUD-17.97%
-47,300.00AUD-75.45%
-192,700.00AUD-245.87%
132,100.00AUD-127.51%
-480,200.00AUD-57.04%
-1.12 MAUD+114.96%
-520,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

Interest Expense of Memphasys is -580,400.00 AUD in 2025.

Interest Expense of Memphasys changed from -132,600.00 AUD to -580,400.00 AUD, representing a 337.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Memphasys since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Memphasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Memphasys

All Key Metrics — Memphasys